July 17, 2017

Biotech Laggards: Verastem, Inc. (NASDAQ:VSTM), ImmunoCellular Therapeutics, Ltd. (NYSE:IMUC), PolarityTE, Inc. (NASDAQ:COOL)

Verastem, Inc. (NASDAQ:VSTM) announced the appointment of Julie B. Feder as Chief Financial Officer. “Julie is an accomplished financial professional with invaluable leadership experience in healthcare, having served as Chief Financial Officer of the Clinton Health Access Initiative and in finance roles of increasing responsibility at Genzyme,” said Robert Forrester, President and Chief Executive Officer of Verastem. “We are delighted to welcome her to our executive team as we look forward to the final data readout of our Phase 3 DUO study evaluating duvelisib in chronic lymphocytic leukemia.”

Verastem, Inc. (NASDAQ:VSTM)’s stock on Friday traded at beginning with a price of $4.090 and when day-trade ended the stock finally moved down -9.83% to reach at $3.71. Analyst’s mean target price for VSTM is $4.38 while analysts mean recommendation is 2.20. Stock value has moved between $1.05 – 4.64 in last one year.

Analyst’s ratings play a very important role in outlining a stock’s performance. Let us check out how analysts have ranked VSTM based on current scenarios. Stock has got OUTPERFORM rating from 2 analyst(s) whereas last month 2 analyst(s) have given outperform rating. SELL rating has been given by 0 analyst(s) and 1 analyst(s) given BUY rating to the stock. Company fiscal year is ending in December and analysts’ consensus recommendation is Outperform for VSTM and estimated EPS for next quarter is $ -0.29 .

Verastem, Inc. (NASDAQ:VSTM) yearly performance is 183.59%. Annual EPS Growth of past 5 years is -7.80%. The current share price indicates that stock is -20.45% away from its one year high and is moving 253.81% ahead of its 52-week low.

On 14 July 2017, ImmunoCellular Therapeutics, Ltd. (NYSE:IMUC) stock price started the day at $1.11 and moved between $1.00 – 1.14 to finally close at $1.03. IMUC’s distance from 20 day simple moving average is -3.81% and distance from 50-Day simple moving average is -14.43%. In last 4 months performance of IMUC was -59.61% while its price to sale ratio is value missing and price to book ratio is 7.92.

Analysts expect ImmunoCellular Therapeutics, Ltd. (NYSE:IMUC) to report $SALES (in millions) EPS and has got OUTPERFORM rating from 0.75 of Thomson Reuters analysts and 0.48 analyst(s) given UNDERPERFORM rating. Analyst’s mean target price for IMUC is $5.00 while analysts mean recommendation is 3.00. Firm LT growth rate is estimated as {92}%.

PolarityTE, Inc. (NASDAQ:COOL)‘s stock on Friday traded at beginning with a price of $25.73 and when day-trade ended the stock finally moved down -5.19% to reach at $24.09. Analyst’s mean target price for COOL is $1.00 while analysts mean recommendation is 3.00. Stock value has moved between $2.61 – 30.11 in last one year.

Stock has got OUTPERFORM rating from 0.66 analyst(s) whereas last month 37.66 analyst(s) have given outperform rating. SELL rating has been given by 3.92 analyst(s) and 0.87 analyst(s) given BUY rating to the stock. Company fiscal year is ending in Quarter Ending Oct-15 and analysts’ consensus recommendation is for COOL and estimated EPS for next quarter is $SALES (in millions) .

PolarityTE, Inc. (NASDAQ:COOL) yearly performance is 395.68% and net profit margin is value missing. Annual EPS Growth of past 5 years is -22.10%. The current share price indicates that stock is -19.94% away from its one year high and is moving 822.99% ahead of its 52-week low.

Leave a Reply

Your email address will not be published. Required fields are marked *